Prenatal Screening and Testing: A Complete Guide for Expectant Parents

The landscape of prenatal testing has changed dramatically over the past two decades. What was once limited to basic ultrasound and a handful of biochemical markers has expanded into a sophisticated, multi-layered programme of genomic analysis, high-resolution imaging, and cell-free DNA technology — capable of detecting conditions with a precision that was unimaginable in previous generations of antenatal care.

For expectant parents, navigating this landscape can feel overwhelming. Understanding what each test measures, what it can and cannot tell you, and how screening results relate to diagnostic certainty is essential to making informed choices at every stage of pregnancy.

This guide explains the full range of prenatal screening tests and prenatal diagnostic tests available across pregnancy, how they differ from one another, what conditions they detect, and what results mean in practice.

What Is Prenatal Screening and Why Does It Matter?

Prenatal screening and testing encompasses two distinct but complementary categories of investigation. Prenatal screening tests assess the statistical probability that a pregnancy is affected by a particular condition — they are non-invasive, carry no procedural risk, and are offered broadly to all or most pregnant patients. Prenatal diagnostic tests, by contrast, provide definitive answers through direct analysis of fetal genetic material, but involve sampling procedures that carry a small risk of pregnancy loss.

The distinction matters because screening and diagnosis serve different clinical functions. A screening result does not confirm a diagnosis — it stratifies risk and identifies pregnancies that warrant further investigation. A diagnostic result, obtained through amniocentesis or chorionic villus sampling, provides a definitive chromosomal or genetic answer. Understanding where each test sits within this framework allows expectant parents to make informed decisions at each stage of the process.

First Trimester Screening

The first trimester — broadly defined as weeks ten to thirteen of pregnancy — is the most information-rich window for early prenatal assessment. Several complementary tests are performed during this period, often in combination to maximise detection rates.

The Nuchal Translucency Test

The nuchal translucency test is an ultrasound measurement taken between eleven and thirteen weeks and six days of gestation. It measures the fluid-filled space at the back of the fetal neck — the nuchal translucency — which tends to be increased in pregnancies affected by chromosomal abnormalities, particularly trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), as well as certain structural cardiac defects.

The NT screening test is not used in isolation. When combined with a maternal blood test measuring pregnancy-associated plasma protein A and free beta-hCG — a combination known as the combined first trimester screen — detection rates for trisomy 21 reach approximately 85 to 90 percent, with a false positive rate of around five percent. The addition of further ultrasound markers including nasal bone assessment, ductus venosus flow, and tricuspid regurgitation can refine this further.

The NIPT Test

The non-invasive prenatal screening test — universally abbreviated as NIPT, and commercially available under brand names including Panorama — represents the most significant advance in antenatal screening of the past two decades. It analyses cell-free fetal DNA circulating in maternal blood from as early as ten weeks of gestation, providing highly accurate probability assessments for the most clinically significant chromosomal abnormalities without any procedural risk to the pregnancy.

NIPT screens with high sensitivity and specificity for:

• Trisomy 21 (Down syndrome) — detection rate exceeding 99%
• Trisomy 18 (Edwards syndrome)
• Trisomy 13 (Patau syndrome)
• Sex chromosome abnormalities including Turner syndrome and Klinefelter syndrome
• Triploidy — a condition in which the fetus has three complete sets of chromosomes rather than two
• Microdeletion syndromes in expanded panels, depending on the test platform

The Panorama test is among the most widely used NIPT platforms internationally and is distinguished by its ability to differentiate fetal from maternal DNA — reducing the rate of false positive results and enabling accurate triploidy detection, which some competing platforms cannot reliably identify.

It is important to understand that NIPT is a screening test, not a diagnostic test. A high-probability result requires confirmation through invasive diagnostic testing before any definitive clinical decisions are made.

Aneuploidy Screening and Chromosomal Abnormalities

Aneuploidy — the presence of an abnormal number of chromosomes — is the primary target of first trimester prenatal screening. The most clinically significant aneuploidies are trisomies, in which an extra copy of a chromosome is present. Trisomy 21, the chromosomal basis of Down syndrome, is the most common viable trisomy and the condition for which prenatal screening was originally developed. Trisomy 18 and trisomy 13 — Patau syndrome — are associated with severe developmental abnormalities and are typically incompatible with prolonged survival outside the womb.

The risk of chromosomal abnormalities increases with maternal age, which is why aneuploidy screening is particularly emphasised for women over 35, though it is now routinely offered regardless of age in most antenatal care settings.

Second Trimester Screening

While first trimester screening provides the earliest risk assessment, second trimester investigations offer additional and complementary information — particularly regarding structural development and conditions not fully captured by earlier tests.

The Prenatal Glucose Test

The prenatal glucose test — also called the glucose challenge test or oral glucose tolerance test depending on the protocol — screens for gestational diabetes mellitus, a condition in which pregnancy hormones impair insulin sensitivity and blood glucose regulation. It is typically performed between 24 and 28 weeks, though earlier testing is recommended for patients with significant risk factors including obesity, a history of gestational diabetes, or a family history of type 2 diabetes.

Undiagnosed and unmanaged gestational diabetes carries risks for both mother and baby, including fetal macrosomia, birth complications, neonatal hypoglycaemia, and an increased long-term risk of type 2 diabetes in the mother. Early identification through the prenatal glucose test allows dietary modification, monitoring, and where necessary, insulin therapy to significantly reduce these risks.

Anomaly Ultrasound and Neural Tube Defects

The mid-trimester anomaly scan — performed at around eighteen to twenty-one weeks — is a detailed structural ultrasound that systematically examines fetal anatomy from brain to spine to heart to abdominal organs. It is the primary tool for identifying structural anomalies including neural tube defects — conditions resulting from incomplete closure of the neural tube during early fetal development.

Neural tube defects include spina bifida, in which the spinal column fails to close completely, and anencephaly, in which major portions of the brain and skull do not develop. The anomaly scan detects the majority of significant neural tube defects, and its sensitivity is further enhanced in centres with high ultrasound expertise and modern equipment. Maternal folic acid supplementation from before conception significantly reduces the risk of neural tube defects and remains a cornerstone of preconception and early pregnancy care.

Pregnancy Blood Test for Maternal Serum Markers

The second trimester maternal serum screening — sometimes called the quadruple test — measures four biochemical markers in maternal blood: alpha-fetoprotein, human chorionic gonadotropin, unconjugated oestriol, and inhibin A. Abnormal patterns of these markers are associated with increased risk of trisomy 21, trisomy 18, and neural tube defects, and the test provides a risk estimate that can be used independently or integrated with first trimester data in a combined sequential screening approach.

Prenatal Diagnostic Tests

Where screening results indicate elevated risk, or where a patient has a personal or family history of a specific genetic condition, prenatal diagnostic tests provide definitive answers through direct chromosomal or genetic analysis of fetal material.

Chorionic Villus Sampling and Amniocentesis

Chorionic villus sampling is performed between ten and thirteen weeks, obtaining a small sample of placental tissue through the cervix or abdominal wall under ultrasound guidance. Amniocentesis is performed from fifteen weeks onwards, sampling amniotic fluid containing fetal cells. Both procedures enable full chromosomal karyotyping, chromosomal microarray analysis for submicroscopic deletions and duplications, and targeted genetic testing for specific inherited conditions. The procedural risk of pregnancy loss is approximately 0.5 to 1 percent for both techniques in experienced hands.

Prenatal Genetic Testing and Expanded Panels

Prenatal genetic testing has expanded considerably with advances in genomic technology. Chromosomal microarray analysis detects copy number variants — small deletions and duplications across the genome — that standard karyotyping misses and that are associated with developmental disability, autism spectrum disorder, and congenital anomalies. Whole exome sequencing of fetal DNA is increasingly available in specialist centres for pregnancies where a structural anomaly has been identified but chromosomal analysis is normal.

Prenatal Paternity Testing

Prenatal paternity testing uses fetal DNA — obtained either non-invasively from maternal blood through cell-free DNA analysis, or invasively through amniocentesis or chorionic villus sampling — to establish biological paternity during pregnancy. Non-invasive prenatal paternity testing is available from as early as seven to eight weeks of gestation and carries no procedural risk to the pregnancy, making it the preferred approach where testing is sought before birth.

Prenatal Screening and Testing in Turkey and at Medical Park Hospitals

Turkey has emerged as a significant destination for antenatal care among international patients, driven by a combination of factors that few competing healthcare markets can match simultaneously. The country's major private hospital groups have invested heavily in maternal-fetal medicine infrastructure over the past decade — bringing in current-generation ultrasound platforms, genomic laboratory capability, and internationally trained specialists in gynecology and obstetrics, clinical genetics, and fetal medicine. For patients from countries where advanced prenatal screening carries prohibitive out-of-pocket costs, or where waiting times delay testing beyond the optimal gestational windows, Turkey offers a clinically equivalent standard of care at substantially lower cost and with significantly faster access.

The regulatory and accreditation framework governing prenatal care in Turkey's leading private hospitals meets international standards, with facilities holding JCI accreditation and laboratory services operating under ISO-certified quality management systems. NIPT platforms including Panorama are processed through accredited international reference laboratories, ensuring that the analytical standards applied to samples taken in Turkey are identical to those in Western European or North American centres.

Prenatal Screening and Testing at Medical Park Hospitals

Medical Park Hospitals provide a comprehensive antenatal screening programme spanning all stages of pregnancy, delivered by specialist teams in Perinatology, Neonatology, Gynecology and Obstetrics, Medical Genetics, and Laboratory medicine. First trimester combined screening, NT ultrasound, NIPT test, prenatal glucose testing, anomaly scanning, and invasive diagnostic procedures are all available within a single integrated pathway — meaning patients move seamlessly from initial screening through to confirmatory diagnosis and genetic counselling without referral outside the network. For international patients coordinating travel around specific gestational windows, Medical Park's patient services team provides scheduling support to ensure that time-sensitive tests.

Counselling sessions are conducted in the patient's preferred language and cover the clinical implications of results, the options available at each decision point, and the onward care pathways within the Medical Park network. Whether an expectant parent is seeking routine first trimester antenatal screening, NIPT for advanced maternal age or elevated risk, or comprehensive prenatal genetic testing following an abnormal anomaly scan, Medical Park's maternal-fetal medicine teams provide the clinical expertise, diagnostic infrastructure, and continuity of care that this critical stage of life demands.

To ensure a seamless transition from prenatal diagnostics to delivery, we invite expectant international parents to further explore our clinical guide on maternal care and childbirth in Turkey.